Kaare Schultz

Biography

Mr. Kaare Schultz has been appointed President and Chief Executive Officer at Teva Pharmaceutical Industries Limited effective November 1, 2017. Mr. Schultz's career, of nearly 30 years within the global pharmaceutical and healthcare industry, includes the following key executive roles: President and Chief Executive Officer at H. Lundbeck A/S (from 2015), President and Chief Operating Officer at Novo Nordisk A/S (2014-2015), Executive Vice President and Chief Operating Officer at Novo Nordisk A/S (2002-2014), has held roles at McKinsey and Anderson Consulting, Chairman of the Board of Directors of Royal Unibrew A/S, member of the Board of Directors at Royal Unibrew A/S (from 2010), member of the Board of Directors at Lego A/S (from 2007) and member of the Board of Directors at Bitten og Mads Clausens Fond (the holding vehicle of Danfoss A/S; from May 2017). Mr. Schultz holds a Masters degree in Economics from University of Copenhagen, Denmark.

Research Interest

Pharmaceutics & Biopharmaceutics Drug Targeting & Drug Development Pharmaceutical Research Pharmaceutical Materials Pharmaceutical Formulations Pharmaceutical Biotechnology